Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/215

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/009770METHODS FOR DEVELOPING CD3+CD8+ CELLS AGAINST MULTIPLE VIRAL EPITOPES FOR TREATMENT OF VIRAL INFECTIONS INCLUDING VARIANTS EVOLVING TO ESCAPE PREVIOUS IMMUNITY
WO 02.02.2023
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/038749 Applicant TEVOGEN BIO, INC. Inventor SAADI, Ryan
Disclosed herein are methods of preparing peptide specific cytotoxic T cells (CTLs) against an emerged strain of a virus. The methods include providing an initial peptide composition specific to a prior strain of a virus, against which prior CTLs were sensitized, wherein the prior CTLs have reduced efficacy against an emerged strain of a virus relative to their efficacy against the prior strain of the virus; identifying an immunodominant peptide against a prior strain of a virus in an initial peptide composition; reducing the proportion of an immunodominant peptide in an initial peptide composition to yield an immunodominant-peptide- diluted peptide composition; and sensitizing mononuclear cells with an immunodominant- peptide-diluted peptide composition, thereby producing expansion of the peptide specific CTLs against an emerged strain of a virus. The virus can be SARS-COV2 (COVID-19) and the emerged strain can be Delta or Omicron BA.2.75.
2.20230033582POLYMERIC NANOPARTICLES FOR ENHANCED CANCER TREATMENT
US 02.02.2023
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
Appl.No 17788671 Applicant THE QUEEN'S UNIVERSITY OF BELFAST Inventor Christopher SCOTT

There is provided polymeric nanoparticles with non-tumour antigen payloads for use in tagging cells for destruction by a subject's immune system and the use thereof for the treatment of cancer. Suitably there is provided a method of treatment comprising administration of nanoparticle comprising a non-tumour protein payload to a subject with cancer, in particular to a cancer cell.

3.WO/2023/006062NUCLEIC ACID VACCINES FOR MUTANT CORONAVIRUS
WO 02.02.2023
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2022/108920 Applicant SUZHOU ABOGEN BIOSCIENCES CO., LTD. Inventor YING, Bo
Provided herein are therapeutic nucleic acid molecules for managing, preventing and/or treating infectious diseases caused by coronavirus. Also provided herein are therapeutic compositions, including vaccines and lipid nanoparticles, comprising the therapeutic nucleic acids and related therapeutic methods and uses.
4.WO/2023/009984COVID-19 IMMUNE RESPONSE ASSAY METHOD
WO 02.02.2023
Int.Class G01N 33/569
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
Appl.No PCT/US2022/074112 Applicant ORASURE TECHNOLOGIES, INC. Inventor YOUNG, Janean A.
Disclosed herein are assay methods and kits for for assessing the strength of the immune response to SARS-CoV-2 virus in a subject by allowing for rapid and efficient detection of neutralizing antibodies (NAbs) from serum of vaccinated and non-vaccinated subjects. The assay method can be conducted in a biosafety level 2 setting, and uses highly-purified, monomeric SARS-Cov-2-Spikel which leads to improved sensitivity and specificity over current state of the art assays.
5.WO/2023/003332PLANT-BASED COVID-19 VARIANT RECOMBINANT SPIKE PROTEIN EXPRESSION VECTOR AND RECOMBINANT PROTEIN USING SAME
WO 26.01.2023
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Appl.No PCT/KR2022/010552 Applicant BIOAPPLICATIONS INC. Inventor SOHN, Eun-Ju
The present invention relates to a plant-based COVID-19 variant recombinant spike protein expression vector, and a recombinant protein using the expression vector, wherein a plant expression system is used such that the recombinant protein does not have the disadvantages of animal-derived recombinant proteins and exhibits an excellent SARS coronavirus 2 prevention and treatment effect, and thus can be effectively utilized as a safe composition for preventing and treating COVID-19.
6.WO/2023/002433COMPOSITIONS AND VACCINES FOR TREATING AND/OR PREVENTING CORONAVIRUS VARIANT INFECTIONS AND METHODS OF USING THE SAME
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IB2022/056759 Applicant ENGENEIC MOLECULAR DELIVERY PTY LTD Inventor BRAHMBHATT, Himanshu
The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.
7.WO/2023/000403SARS-COV-2 SUBPROTEIN NANO-VACCINE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2021/111511 Applicant WUHAN SHENGRUN BIOTECHNOLOGY CO., LTD. Inventor ZHENG, Junwu
A Sars-Cov-2 subprotein nano-vaccine, and a preparation method therefor and an application thereof. The nano-vaccine comprises: an organic compound self-assembled from polylactic acid, porphyrin, or a porphyrin derivative, and a Co2+ ion conjugate; Sars-Cov-2 antigen protein; a vaccine adjuvant; and a lipid. The synthetic organic compound has an adjuvant encapsulated in its core and a Sars-Cov-2 antigen protein efficiently loaded on the surface, such that a nano-vaccine system allowing for co-delivery of the Sars-Cov-2 antigen protein and vaccine adjuvant is realized, thereby maximizing the immunogenicity of the Sars-Cov-2 recombinant subprotein and enabling tracking the distribution of the subprotein in an organism by means of fluorescent molecules. In addition, the nano-vaccine is also linked with a polypeptide that can specifically target antigen-presenting cells, so as to promote the uptake of the nano-vaccine by DC cells and promote anti-viral response. The preparation method is simple and efficient and provides a way for effectively preventing Sars-Cov-2 infection.
8.WO/2023/001259PREPARATION AND APPLICATION OF RECOMBINANT MULTIVALENT NOVEL CORONAVIRUS TRIMER PROTEIN VACCINE CAPABLE OF INDUCING BROAD-SPECTRUM AND NEUTRALIZING ACTIVITY
WO 26.01.2023
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/107213 Applicant SINOCELLTECH LTD Inventor XIE, Liangzhi
A recombinant multivalent novel coronavirus trimer protein vaccine capable of inducing broad-spectrum and neutralizing activity. The recombinant protein component comprises, but is not limited to, a homotrimer protein formed by introducing, into an extracellular domain (ECD) of B.1.617.1 strain and B.1.617.2 strain spike (S) proteins, a mutation site and a trimerization assistance structure. The multivalent vaccine comprises an ECD trimer protein of a single component or any combination of components of the variant strains above, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immunity and cellular immunity. The multivalent novel coronavirus trimer protein vaccine can be used for preventing infection-related diseases caused by infection of novel coronavirus and variant strains thereof.
9.WO/2023/002505ASSAY FOR DETECTION OF EPIDEMIOLOGICALLY IMPORTANT SARS- COV-2 VARIANTS
WO 26.01.2023
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/IN2022/050649 Applicant INDIAN COUNCIL OF MEDICAL RESEARCH Inventor NANDI, Shyam Sundar
The present invention relates to novel oligonucleotide sequences for rapid screening of epidemiologically important variants of SARS-CoV-2, wherein said oligonucleotide sequences acts as primers for amplification of sequences having Single-nucleotide polymorphisms (SNP)/mutations in the spike glycoprotein gene. The invention also relates to an assay for rapid screening of epidemiologically important variants of SARS-CoV-2 based upon using novel oligonucleotide sequences as primers. In particular, invention relates to oligonucleotide sequences of SEQ ID Nos. 1 – 37 for rapid screening of epidemiologically important variants of SARS-CoV-2.
10.WO/2023/004415SARS-COV-2 VACCINE USING BACTERIAL SPORES EXPRESSING ANTIGENIC FRAGMENTS
WO 26.01.2023
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2022/074048 Applicant UNIVERSITY OF MIAMI Inventor MIRSAEIDI, Mehdi
Disclosed are compositions comprising a SARS-CoV-2 vaccine that can be administered orally. The vaccine can be on a platform comprising a spore coat protein from a spore forming bacteria, such as Bacillus subtilis. Also disclosed are methods of preventing or treating a COVID-19 infection comprising providing the SARS-CoV-2 vaccine to a subject.